Jason Butler
Stock Analyst at JMP Securities
(2.15)
# 2,624
Out of 4,832 analysts
139
Total ratings
35.25%
Success rate
-3.67%
Average return
Main Sectors:
Stocks Rated by Jason Butler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRTA Prothena Corporation | Maintains: Market Outperform | $80 → $78 | $6.89 | +1,032.90% | 9 | May 9, 2025 | |
| TTD The Trade Desk | Maintains: Market Outperform | $115 → $100 | $79.14 | +26.36% | 1 | May 9, 2025 | |
| VRDN Viridian Therapeutics | Maintains: Market Outperform | $42 → $38 | $12.38 | +206.95% | 8 | May 7, 2025 | |
| ABVX ABIVAX Société Anonyme | Reiterates: Market Outperform | $33 | $6.06 | +444.55% | 3 | Apr 30, 2025 | |
| CYTK Cytokinetics | Reiterates: Market Outperform | $78 | $30.00 | +160.00% | 16 | Apr 10, 2025 | |
| RAPP Rapport Therapeutics | Initiates: Market Outperform | $28 | $9.63 | +190.76% | 1 | Apr 8, 2025 | |
| PGEN Precigen | Reiterates: Market Outperform | $6 | $1.28 | +368.75% | 9 | Mar 20, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Market Outperform | $17 → $18 | $8.14 | +121.13% | 2 | Mar 12, 2025 | |
| ESPR Esperion Therapeutics | Reiterates: Market Outperform | $4 | $0.73 | +447.95% | 7 | Mar 5, 2025 | |
| ARGX argenx SE | Maintains: Outperform | $696 → $701 | $532.27 | +31.70% | 8 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $29 → $33 | $9.40 | +251.06% | 1 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $8 → $9 | $3.49 | +157.88% | 8 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $22 | $2.37 | +828.27% | 4 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $72 → $73 | $47.91 | +52.37% | 13 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $9 | $2.22 | +305.41% | 7 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $39 | $10.11 | +285.76% | 4 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.26 | - | 7 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $50 → $23 | $1.41 | +1,531.21% | 3 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $19 | $11.62 | +63.51% | 6 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $44 → $39 | $17.16 | +127.34% | 13 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $22 | $0.65 | +3,289.83% | 1 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.54 | - | 1 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $42,000 | $7.65 | +548,919.61% | 1 | Dec 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $111 → $116 | $5.15 | +2,152.43% | 4 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $9 | $3.16 | +184.81% | 1 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.29 | - | 1 | Dec 2, 2020 |
Prothena Corporation
May 9, 2025
Maintains: Market Outperform
Price Target: $80 → $78
Current: $6.89
Upside: +1,032.90%
The Trade Desk
May 9, 2025
Maintains: Market Outperform
Price Target: $115 → $100
Current: $79.14
Upside: +26.36%
Viridian Therapeutics
May 7, 2025
Maintains: Market Outperform
Price Target: $42 → $38
Current: $12.38
Upside: +206.95%
ABIVAX Société Anonyme
Apr 30, 2025
Reiterates: Market Outperform
Price Target: $33
Current: $6.06
Upside: +444.55%
Cytokinetics
Apr 10, 2025
Reiterates: Market Outperform
Price Target: $78
Current: $30.00
Upside: +160.00%
Rapport Therapeutics
Apr 8, 2025
Initiates: Market Outperform
Price Target: $28
Current: $9.63
Upside: +190.76%
Precigen
Mar 20, 2025
Reiterates: Market Outperform
Price Target: $6
Current: $1.28
Upside: +368.75%
Zevra Therapeutics
Mar 12, 2025
Maintains: Market Outperform
Price Target: $17 → $18
Current: $8.14
Upside: +121.13%
Esperion Therapeutics
Mar 5, 2025
Reiterates: Market Outperform
Price Target: $4
Current: $0.73
Upside: +447.95%
argenx SE
Feb 28, 2025
Maintains: Outperform
Price Target: $696 → $701
Current: $532.27
Upside: +31.70%
Feb 21, 2025
Maintains: Market Outperform
Price Target: $29 → $33
Current: $9.40
Upside: +251.06%
Feb 13, 2025
Maintains: Market Outperform
Price Target: $8 → $9
Current: $3.49
Upside: +157.88%
Nov 26, 2024
Reiterates: Market Outperform
Price Target: $22
Current: $2.37
Upside: +828.27%
Nov 1, 2024
Maintains: Market Outperform
Price Target: $72 → $73
Current: $47.91
Upside: +52.37%
Oct 8, 2024
Reiterates: Market Outperform
Price Target: $9
Current: $2.22
Upside: +305.41%
Sep 4, 2024
Reiterates: Market Outperform
Price Target: $39
Current: $10.11
Upside: +285.76%
Sep 4, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $0.26
Upside: -
Jul 26, 2024
Maintains: Market Outperform
Price Target: $50 → $23
Current: $1.41
Upside: +1,531.21%
Apr 9, 2024
Reiterates: Market Outperform
Price Target: $19
Current: $11.62
Upside: +63.51%
Mar 12, 2024
Maintains: Outperform
Price Target: $44 → $39
Current: $17.16
Upside: +127.34%
Sep 28, 2023
Initiates: Market Outperform
Price Target: $22
Current: $0.65
Upside: +3,289.83%
Oct 17, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.54
Upside: -
Dec 15, 2021
Initiates: Market Outperform
Price Target: $42,000
Current: $7.65
Upside: +548,919.61%
Nov 23, 2021
Maintains: Market Outperform
Price Target: $111 → $116
Current: $5.15
Upside: +2,152.43%
Nov 8, 2021
Maintains: Market Outperform
Price Target: $7 → $9
Current: $3.16
Upside: +184.81%
Dec 2, 2020
Downgrades: Market Perform
Price Target: n/a
Current: $0.29
Upside: -